[go: up one dir, main page]

RU2009107138A - MEDICINE FOR POISONING - Google Patents

MEDICINE FOR POISONING Download PDF

Info

Publication number
RU2009107138A
RU2009107138A RU2009107138/15A RU2009107138A RU2009107138A RU 2009107138 A RU2009107138 A RU 2009107138A RU 2009107138/15 A RU2009107138/15 A RU 2009107138/15A RU 2009107138 A RU2009107138 A RU 2009107138A RU 2009107138 A RU2009107138 A RU 2009107138A
Authority
RU
Russia
Prior art keywords
toxin
protein
amino acid
acid sequence
drug according
Prior art date
Application number
RU2009107138/15A
Other languages
Russian (ru)
Other versions
RU2465893C2 (en
Inventor
АЙХЕЛЬШТРАЙБЕР Кристоф ФОН (DE)
Айхельштрайбер Кристоф фон
Джессика РАЙНЕКЕ (DE)
Джессика РАЙНЕКЕ
Штефан ТЕНЦЕР (DE)
Штефан Тенцер
Хансйорг ШИЛЬД (DE)
Хансйорг Шильд
Майа РУПНИК (SI)
Майа РУПНИК
Original Assignee
Йоханнес Гутенберг-Университет Майнц (De)
Йоханнес Гутенберг-Университет Майнц
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006036373A external-priority patent/DE102006036373A1/en
Priority claimed from DE102007004938A external-priority patent/DE102007004938A1/en
Application filed by Йоханнес Гутенберг-Университет Майнц (De), Йоханнес Гутенберг-Университет Майнц filed Critical Йоханнес Гутенберг-Университет Майнц (De)
Publication of RU2009107138A publication Critical patent/RU2009107138A/en
Application granted granted Critical
Publication of RU2465893C2 publication Critical patent/RU2465893C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1. Лекарственное средство для предупреждения или ослабления отравления токсинами LCT (большими клостридиальными цитотоксинами), отличающееся тем, что оно содержит в качестве активного вещества, по меньшей мере, один эффектор, а именно ингибитор или активатор активности протеазы токсинов LCT. ! 2. Лекарственное средство по п.1, отличающееся тем, что активным веществом является эффектор, а именно ингибитор или активатор активности протеазы токсина А (TcdA) Clostridium difficile и/или токсина В (TcdB) Clostridium difficile и/или летального токсина (TcsL) Clostridium sordellii и/или α-токсина (Tcnα) Clostridium novyi. ! 3. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является 1,2-эпокси-3-(р-нитрофенокси)-пропан (EPNP). ! 4. Лекарственное средство по п.1, отличающееся тем, что активатором является инозитолфосфат, предпочтительно инозитолгексафосфат (IP6). ! 5. Лекарственное средство по п.1 или 2, отличающееся тем, что эффектором является состязательно ингибирующий структурный аналог инозитолфосфата, предпочтительно инозитолгексафосфата (IP6). ! 6. Лекарственное средство по п.1 или 2, отличающееся тем, что активатором является вещество, повышающее аналогично IP6 (автокаталитическую) активность протеазы токсинов LCT, в частности токсина TcdA, и/или TcdB, и/или TcsL, и/или Tcnα. ! 7. Лекарственное средство по п.1 или 2, отличающееся тем, что эффектором является химическое вещество, обеспечивающее снижение концентрации инозитолфосфата в просвете кишечника млекопитающих, в частности людей. ! 8. Лекарственное средство по п.1 или 2, отличающееся тем, что эффектором является химическое вещество, обеспечивающее снижение концентрации инозитолфосфата в клетках млекопитающих, в частно 1. A medicament for preventing or attenuating poisoning by LCT toxins (large clostridial cytotoxins), characterized in that it contains at least one effector as an active substance, namely an inhibitor or activator of the protease activity of LCT toxins. ! 2. The drug according to claim 1, characterized in that the active substance is an effector, namely an inhibitor or activator of the protease activity of the toxin A (TcdA) Clostridium difficile and / or toxin B (TcdB) Clostridium difficile and / or lethal toxin (TcsL) Clostridium sordellii and / or α-toxin (Tcnα) Clostridium novyi. ! 3. The drug according to claim 1 or 2, characterized in that the inhibitor is 1,2-epoxy-3- (p-nitrophenoxy) propane (EPNP). ! 4. The drug according to claim 1, characterized in that the activator is inositol phosphate, preferably inositol hexaphosphate (IP6). ! 5. The drug according to claim 1 or 2, characterized in that the effector is a competitively inhibiting structural analogue of inositol phosphate, preferably inositol hexaphosphate (IP6). ! 6. The drug according to claim 1 or 2, characterized in that the activator is a substance that increases similarly to IP6 (autocatalytic) activity of the protease of LCT toxins, in particular the toxin TcdA, and / or TcdB, and / or TcsL, and / or Tcnα. ! 7. The drug according to claim 1 or 2, characterized in that the effector is a chemical substance that ensures a decrease in the concentration of inositol phosphate in the lumen of the intestines of mammals, in particular humans. ! 8. The drug according to claim 1 or 2, characterized in that the effector is a chemical substance that reduces the concentration of inositol phosphate in mammalian cells, in particular

Claims (20)

1. Лекарственное средство для предупреждения или ослабления отравления токсинами LCT (большими клостридиальными цитотоксинами), отличающееся тем, что оно содержит в качестве активного вещества, по меньшей мере, один эффектор, а именно ингибитор или активатор активности протеазы токсинов LCT.1. A medicament for preventing or attenuating poisoning by LCT toxins (large clostridial cytotoxins), characterized in that it contains at least one effector as an active substance, namely an inhibitor or activator of the protease activity of LCT toxins. 2. Лекарственное средство по п.1, отличающееся тем, что активным веществом является эффектор, а именно ингибитор или активатор активности протеазы токсина А (TcdA) Clostridium difficile и/или токсина В (TcdB) Clostridium difficile и/или летального токсина (TcsL) Clostridium sordellii и/или α-токсина (Tcnα) Clostridium novyi.2. The drug according to claim 1, characterized in that the active substance is an effector, namely an inhibitor or activator of the protease activity of the toxin A (TcdA) Clostridium difficile and / or toxin B (TcdB) Clostridium difficile and / or lethal toxin (TcsL) Clostridium sordellii and / or α-toxin (Tcnα) Clostridium novyi. 3. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является 1,2-эпокси-3-(р-нитрофенокси)-пропан (EPNP).3. The drug according to claim 1 or 2, characterized in that the inhibitor is 1,2-epoxy-3- (p-nitrophenoxy) propane (EPNP). 4. Лекарственное средство по п.1, отличающееся тем, что активатором является инозитолфосфат, предпочтительно инозитолгексафосфат (IP6).4. The drug according to claim 1, characterized in that the activator is inositol phosphate, preferably inositol hexaphosphate (IP6). 5. Лекарственное средство по п.1 или 2, отличающееся тем, что эффектором является состязательно ингибирующий структурный аналог инозитолфосфата, предпочтительно инозитолгексафосфата (IP6).5. The drug according to claim 1 or 2, characterized in that the effector is a competitively inhibiting structural analogue of inositol phosphate, preferably inositol hexaphosphate (IP6). 6. Лекарственное средство по п.1 или 2, отличающееся тем, что активатором является вещество, повышающее аналогично IP6 (автокаталитическую) активность протеазы токсинов LCT, в частности токсина TcdA, и/или TcdB, и/или TcsL, и/или Tcnα.6. The drug according to claim 1 or 2, characterized in that the activator is a substance that increases similarly to IP6 (autocatalytic) activity of the protease of LCT toxins, in particular the toxin TcdA, and / or TcdB, and / or TcsL, and / or Tcnα. 7. Лекарственное средство по п.1 или 2, отличающееся тем, что эффектором является химическое вещество, обеспечивающее снижение концентрации инозитолфосфата в просвете кишечника млекопитающих, в частности людей.7. The drug according to claim 1 or 2, characterized in that the effector is a chemical substance that ensures a decrease in the concentration of inositol phosphate in the lumen of the intestines of mammals, in particular humans. 8. Лекарственное средство по п.1 или 2, отличающееся тем, что эффектором является химическое вещество, обеспечивающее снижение концентрации инозитолфосфата в клетках млекопитающих, в частности людей.8. The drug according to claim 1 or 2, characterized in that the effector is a chemical substance that ensures a decrease in the concentration of inositol phosphate in mammalian cells, in particular humans. 9. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с активным центром протеазы в протеиновой области токсина TcdB от AS 1500 до AS 1800 согласно аминокислотной последовательности токсина TcdB, №Р18177 (SwissProt/TrEMBL).9. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the active center of the protease in the protein region of the TcdB toxin from AS 1500 to AS 1800 according to the amino acid sequence of the TcdB toxin No. P18177 (SwissProt / TrEMBL). 10. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина TcdB от AS 1653 до AS 1678 согласно аминокислотной последовательности токсина TcdB, №Р18177 (SwissProt/TrEMBL).10. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the TcdB toxin from AS 1653 to AS 1678 according to the amino acid sequence of the TcdB toxin, No.P18177 ( SwissProt / TrEMBL). 11. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с мотивом DXG в аминокислотном положении AS 1665 протеина токсина TcdB согласно аминокислотной последовательности токсина TcdB, №P18177 (SwissProt/TrEMBL).11. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the DXG motif at amino acid position AS 1665 of the TcdB toxin protein according to the amino acid sequence of the TcdB toxin, No. P18177 ( SwissProt / TrEMBL). 12. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина TcdA от AS 1651 до AS 1675 согласно аминокислотной последовательности токсина TcdA, №P16154 (SwissProt/TrEMBL).12. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the TcdA toxin from AS 1651 to AS 1675 according to the amino acid sequence of the TcdA toxin, No. P16154 ( SwissProt / TrEMBL). 13. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с мотивом DXG в аминокислотном положении AS 1662 протеина токсина TcdA согласно аминокислотной последовательности №Р16154 (SwissProt/TrEMBL).13. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the DXG motif at amino acid position AS 1662 of the TcdA toxin protein according to amino acid sequence No. P16154 (SwissProt / TrEMBL ) 14. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина TcsL от AS 1654 до AS согласно аминокислотной последовательности токсина TcsL, №Q46342 (SwissProt/TrEMBL).14. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the TcsL toxin from AS 1654 to AS according to the amino acid sequence of the TcsL toxin, No. Q46342 (SwissProt / TrEMBL). 15. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с мотивом DXG в аминокислотном положении AS 1666 протеина токсина TcsL согласно аминокислотной последовательности токсина TcsL, №Q46342 (SwissProt/TrEMBL).15. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the DXG motif at amino acid position AS 1666 of the TcsL toxin protein according to the amino acid sequence of the TcsL toxin, No. Q46342 ( SwissProt / TrEMBL). 16. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина Tcnα от AS 1641 до AS 1665 согласно аминокислотной последовательности токсина Tcnα, №Q46149 (SwissProt/TrEMBL).16. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the Tcnα toxin from AS 1641 to AS 1665 according to the amino acid sequence of the Tcnα toxin, No. Q46149 ( SwissProt / TrEMBL). 17. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина TcsB от AS 1400 до AS 2300 согласно аминокислотной последовательности токсина TcsB, №P18177 (SwissProt/TrEMBL) или с эквивалентными или гомологичными протеиновыми областями токсина TcdA или TcsL или Tcnα.17. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the TcsB toxin from AS 1400 to AS 2300 according to the amino acid sequence of the TcsB toxin, No. P18177 ( SwissProt / TrEMBL) or with equivalent or homologous protein regions of the TcdA or TcsL or Tcnα toxin. 18. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина TcsB от AS 1517 до AS 2142 согласно аминокислотной последовательности токсина TcsB, №Р18177 (SwissProt/TrEMBL) или с эквивалентными или гомологичными протеиновыми областями токсина TcdA или TcsL или Tcnα.18. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the TcsB toxin from AS 1517 to AS 2142 according to the amino acid sequence of the TcsB toxin, No.P18177 ( SwissProt / TrEMBL) or with equivalent or homologous protein regions of the TcdA or TcsL or Tcnα toxin. 19. Лекарственное средство по п.1 или 2, отличающееся тем, что ингибитором является химическое вещество, в частности протеин, а именно антитело, которое взаимодействует с протеиновой областью токсина TcsB от AS 1517 до AS 1593 или от AS 1918 до AS 2142 согласно аминокислотной последовательности токсина TcsB, №Р18177 (SwissProt/TrEMBL), или с эквивалентными или гомологичными протеиновыми областями токсина TcdA или TcsL или Tcnα.19. The drug according to claim 1 or 2, characterized in that the inhibitor is a chemical substance, in particular a protein, namely an antibody that interacts with the protein region of the TcsB toxin from AS 1517 to AS 1593 or from AS 1918 to AS 2142 according to amino acid TcsB toxin sequences, No. P18177 (SwissProt / TrEMBL), or with equivalent or homologous protein regions of the TcdA or TcsL or Tcnα toxin. 20. Лекарственное средство для предупреждения или ослабления отравления токсинами LCT, отличающееся тем, что оно:20. A medicament for preventing or reducing poisoning by LCT toxins, characterized in that it: (1) пригодно для назначения в качестве вакцины и(1) is suitable for administration as a vaccine and (2) в качестве антигенного активного вещества(2) as an antigenic active substance (а) содержит тот фрагмент протеина токсина TcdB аминокислотной последовательности №Р18177 (SwissProt/TrEMBL), который включает в себя, по меньшей мере, один мотив DXG в положении 1665, предпочтительно аминокислотную последовательность в положениях от AS 1653 до AS 1678, более предпочтительно аминокислотную последовательность от AS 1500 до AS 1800, (a) contains that fragment of the TcdB toxin protein of amino acid sequence No.P18177 (SwissProt / TrEMBL), which includes at least one DXG motif at position 1665, preferably an amino acid sequence at positions from AS 1653 to AS 1678, more preferably amino acid sequence from AS 1500 to AS 1800, (b) и/или содержит тот фрагмент протеина токсина TcdA аминокислотной последовательности №Р16154 (SwissProt/TrEMBL), который включает в себя, по меньшей мере, один мотив DXG в положении 1662, предпочтительно аминокислотную последовательность в положениях от AS 1651 до AS 1675, (b) and / or contains that fragment of the TcdA toxin protein of amino acid sequence No. P16154 (SwissProt / TrEMBL), which includes at least one DXG motif at position 1662, preferably an amino acid sequence at positions from AS 1651 to AS 1675, (с) и/или содержит тот фрагмент протеина токсина TcsL его аминокислотной последовательности №Q46342 (SwissProt/TrEMBL), который включает в себя, по меньшей мере, один мотив DXG в положении 1666, предпочтительно аминокислотную последовательность в ее положениях от AS 1654 до AS 1679, (c) and / or contains that fragment of the TcsL toxin protein of its amino acid sequence No. Q46342 (SwissProt / TrEMBL), which includes at least one DXG motif at position 1666, preferably the amino acid sequence at its positions from AS 1654 to AS 1679, (d) и/или содержит тот фрагмент протеина токсина Tcnα его аминокислотной последовательности №Q46149 (SwissProt/TrEMBL), который включает в себя, по меньшей мере, одну аминокислотную последовательность в ее положениях от AS 1641 до AS 1665.  (d) and / or contains that fragment of the Tcnα toxin protein of its amino acid sequence No. Q46149 (SwissProt / TrEMBL), which includes at least one amino acid sequence at its positions from AS 1641 to AS 1665.
RU2009107138/15A 2006-08-02 2007-05-26 Anti-poisoning medication RU2465893C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006036373A DE102006036373A1 (en) 2006-08-02 2006-08-02 Medicines for LCT poisoning
DE102006036373.6 2006-08-02
DE102007004938.4 2007-01-26
DE102007004938A DE102007004938A1 (en) 2007-01-26 2007-01-26 Medicament for avoiding or alleviating large clostridial cytotoxins, comprises an effector, which is an inhibitor or activator of the protease activity of large clostridial cytotoxins

Publications (2)

Publication Number Publication Date
RU2009107138A true RU2009107138A (en) 2010-09-10
RU2465893C2 RU2465893C2 (en) 2012-11-10

Family

ID=38521891

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009107138/15A RU2465893C2 (en) 2006-08-02 2007-05-26 Anti-poisoning medication

Country Status (9)

Country Link
US (3) US20090311258A1 (en)
EP (1) EP2054044B1 (en)
JP (2) JP5345532B2 (en)
AU (1) AU2007280861B2 (en)
CA (1) CA2659684A1 (en)
ES (1) ES2507553T3 (en)
RU (1) RU2465893C2 (en)
UA (1) UA96768C2 (en)
WO (1) WO2008014733A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311258A1 (en) * 2006-08-02 2009-12-17 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
KR20110100189A (en) * 2008-12-03 2011-09-09 베링거잉겔하임베트메디카게엠베하 Vaccine Production Method
ES2727633T3 (en) * 2011-09-29 2019-10-17 Eth Zuerich Pharmaceutical compounds for use in the therapy of Clostridium difficile infection
KR20140101835A (en) 2011-12-08 2014-08-20 노파르티스 아게 Clostridium difficile toxin-based vaccine
HK1200463A1 (en) * 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
CN111499738B (en) * 2020-06-03 2022-04-05 郑州师范学院 An antibody against Clostridium difficile enterotoxin A
WO2025097230A1 (en) * 2023-11-08 2025-05-15 Fundação Oswaldo Cruz Molecule of recombinant nucleic acid, epitope of alpha toxin of recombinant c. novyi and use thereof, expression vector, vaccine composition, method for preventing or treating clostridiosis in an individual suffering from same and method for producing a vaccine composition against clostridiosis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
JPH0429621Y2 (en) * 1988-01-23 1992-07-17
JPH01287035A (en) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd Drug, preventive and remedy of alcoholism
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
FR2770844A1 (en) * 1997-11-10 1999-05-14 Inst Nat Sante Rech Med INHIBITORS OF CLOSTRIDAL TOXINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6415234B1 (en) * 1998-08-03 2002-07-02 Glyco Design Inc. Designing inhibitors for glycosyltransferases
AU5122700A (en) * 1999-04-09 2000-11-14 Johns Hopkins University, The Channel forming toxins as antiviral agents
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2001044272A2 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
CA2488230C (en) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
RU2312672C2 (en) * 2002-06-26 2007-12-20 Нестек С.А. Composition against inflammatory process
US8038986B2 (en) * 2002-07-26 2011-10-18 The Walter And Eliza Hall Institute Of Medical Research Immunogenic compositions and diagnostic and therapeutic uses thereof
JP4557514B2 (en) * 2003-07-15 2010-10-06 住友電工焼結合金株式会社 Internal gear pump and inner rotor of the pump
ES2643760T3 (en) * 2004-02-06 2017-11-24 University Of Massachusetts Antibodies against Clostridium difficile toxins and their uses
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
KR100852821B1 (en) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 Therapeutic composition comprising botulinum neurotoxin
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US20060099169A1 (en) * 2004-10-13 2006-05-11 Ilypsa, Inc. Toxin binding compositions
EP1807439A2 (en) * 2004-10-25 2007-07-18 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
WO2007060618A2 (en) * 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Macrolides derivatives as antibacterial agents
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20090311258A1 (en) * 2006-08-02 2009-12-17 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
US20110218176A1 (en) * 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8110551B2 (en) * 2008-01-22 2012-02-07 The Trustees Of The University Of Pennsylvania Cytolethal distending toxin and use thereof
KR20110100189A (en) * 2008-12-03 2011-09-09 베링거잉겔하임베트메디카게엠베하 Vaccine Production Method
US20100137563A1 (en) * 2008-12-03 2010-06-03 Northwestern University Cysteine Protease Autoprocessing of Fusion Proteins
WO2011034622A2 (en) * 2009-09-21 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
CN105732767A (en) * 2009-09-25 2016-07-06 夏尔孤儿治疗有限公司 Novel NPR-B agonists
WO2012138963A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof
RU2754446C2 (en) * 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Compositions related to mutant toxin clostridium difficile and their application methods
US9770500B2 (en) * 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
ES2727633T3 (en) * 2011-09-29 2019-10-17 Eth Zuerich Pharmaceutical compounds for use in the therapy of Clostridium difficile infection

Also Published As

Publication number Publication date
US20150344531A1 (en) 2015-12-03
AU2007280861A1 (en) 2008-02-07
EP2054044B1 (en) 2014-07-23
US20090311258A1 (en) 2009-12-17
US9066961B2 (en) 2015-06-30
JP2009545536A (en) 2009-12-24
US20130280286A1 (en) 2013-10-24
CA2659684A1 (en) 2008-02-07
EP2054044A1 (en) 2009-05-06
JP2013067630A (en) 2013-04-18
WO2008014733A1 (en) 2008-02-07
UA96768C2 (en) 2011-12-12
AU2007280861B2 (en) 2013-02-07
ES2507553T3 (en) 2014-10-15
JP5777594B2 (en) 2015-09-09
JP5345532B2 (en) 2013-11-20
WO2008014733A9 (en) 2009-01-29
RU2465893C2 (en) 2012-11-10

Similar Documents

Publication Publication Date Title
RU2009107138A (en) MEDICINE FOR POISONING
Bryzek et al. Triggering NETosis via protease-activated receptor (PAR)-2 signaling as a mechanism of hijacking neutrophils function for pathogen benefits
Galdino et al. Disarming Pseudomonas aeruginosa virulence by the inhibitory action of 1, 10-phenanthroline-5, 6-dione-based compounds: Elastase B (lasB) as a chemotherapeutic target
Omura et al. A newly derived protein from Bacillus subtilis natto with both antithrombotic and fibrinolytic effects
Bartolini et al. Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer: focus on short and long-term outcomes
Flores-Dı́az et al. Role of Clostridium perfringens phospholipase C in the pathogenesis of gas gangrene
Tan et al. Cross reactivity and lethality neutralization of venoms of Indonesian Trimeresurus complex species by Thai Green Pit Viper Antivenom
Zacharski et al. Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?
Mukherjee A major phospholipase A2 from Daboia russelii russelii venom shows potent anticoagulant action via thrombin inhibition and binding with plasma phospholipids
Sampat et al. Unraveling snake venom phospholipase A2: an overview of its structure, pharmacology, and inhibitors
Higuchi et al. Purification and partial characterization of two phospholipases A2 from Bothrops leucurus (white-tailed-jararaca) snake venom
CN101802188A (en) Antidotes for factor XA inhibitors and methods of use thereof
Souza et al. Koninginins, phospholipase A2 inhibitors from endophytic fungus Trichoderma koningii
Chandrahas et al. Direct host plasminogen binding to bacterial surface M-protein in pattern D strains of Streptococcus pyogenes is required for activation by its natural coinherited SK2b protein
Rengasamy et al. Bioactive peptides and proteins as alternative antiplatelet drugs
Cortes-Selva et al. Metabolic reprogramming of the myeloid lineage by Schistosoma mansoni infection persists independently of antigen exposure
Zhang et al. Type I collagen or gelatin stimulates mouse peritoneal macrophages to aggregate and produce pro-inflammatory molecules through upregulated ROS levels
EP3684351A1 (en) Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease
LaMont et al. Role of clostridial toxin in the pathogenesis of clindamycin colitis in rabbits
Sapsutthipas et al. Effective equine immunization protocol for production of potent poly-specific antisera against Calloselasma rhodostoma, Cryptelytrops albolabris and Daboia siamensis
Wilhelm Chemical mediators. I
TW201026852A (en) Process for production of vaccines
Sun et al. Neuronal nitric oxide synthase in dorsal raphe nucleus mediates PTSD-like behaviors induced by single-prolonged stress through inhibiting serotonergic neurons activity
Jiang et al. Inhibitory effect of salicin on Staphylococcus aureus coagulase
Yang et al. Targeting formyl peptide receptor 1 with anteiso‐C13‐surfactin for neutrophil‐dominant acute respiratory distress syndrome

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170527